NA
KPRX icon

NewEdge Advisors’s Kiora Pharmaceuticals KPRX Stock Holding History

NewEdge Advisors’s Portfolio KPRX Stock Details KPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-22
Closed -$42 – 4297
2026
Q1 		$42 Hold
22
– – ﹤0.01% 4100
2025
Q4 		$43 Hold
22
– – ﹤0.01% 4176
2025
Q3 		$61 Hold
22
– – ﹤0.01% 4051
2025
Q2 		$63 Hold
22
– – ﹤0.01% 3920
2025
Q1 		$66 Hold
22
– – ﹤0.01% 3840
2024
Q4 		$73 Hold
22
– – ﹤0.01% 3803
2024
Q3 		$81 Hold
22
– – ﹤0.01% 3728
2024
Q2 		$92 Hold
22
– – ﹤0.01% 3691
2024
Q1 		$141 Hold
22
– – ﹤0.01% 3691
2023
Q4 		$104 Hold
22
– – ﹤0.01% 3638
2023
Q3 		$114 Hold
22
– – ﹤0.01% 3363
2023
Q2 		$129 Hold
22
– – ﹤0.01% 3411
2023
Q1 		$668 Buy
+22
New +$822 ﹤0.01% 3207

Other funds holding KPRX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SRL
Scientech Research LLC Jersey City, New Jersey $123M AUM 198.31% 1-Year Est. Return

NewEdge Advisors's KPRX Position: Q2 2026 in Review

NewEdge Advisors sold out of Kiora Pharmaceuticals (KPRX) in Q2 2026, closing a stake of 22 shares — an estimated $42 sold.

NewEdge Advisors first reported a position in KPRX in Q1 2023 and held it in 13 quarters. The position peaked at $668 in Q1 2023. 22 funds tracked by Wall St. Rank hold KPRX as of Q2 2026.

  • NewEdge Advisors reported no remaining Kiora Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • NewEdge Advisors sold 22 Kiora Pharmaceuticals shares in Q2 2026, an estimated $42.
  • NewEdge Advisors first reported a position in Kiora Pharmaceuticals in Q1 2023 and held it in 13 quarters.
  • NewEdge Advisors's Kiora Pharmaceuticals position peaked at $668 in Q1 2023.
  • 22 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.